Back to Authors

Investigators, on behalf of the TORREY Study

A5056708991

Mayo Clinic

No affiliation available

Citations 2

Interim Results From the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)

A14. BUILDING LEGO(LAND): LESSONS LEARNED FROM LARGE SCALE CLINICAL TRIALS IN PAH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1011-A1011

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1011

Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial

D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A6726-A6726

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6726